GlassScriptPhysician profile
Athena Moon
NPI 1528511169
$2,848.85
in general payments reported to CMS, 2019-2025
17 companies · $978 in 2025
The $978 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $394 · 2022: $280 · 2023: $388 · 2024: $808 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,113 · Education: $61.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,112.60 |
| Education | $61.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $811.46 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $477.18 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $395.83 | 2022-2025 | |
| Lilly USA, LLC | $247.93 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $184.72 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $163.45 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.39 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $87.27 | 2021-2024 | Rexulti |
| Amgen INC. | $83.40 | 2021-2022 | |
| Astellas Pharma US INC | $61.95 | 2023 | |
| Glaxosmithkline, LLC. | $58.24 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $52.00 | 2024-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $24.71 | 2025 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $23.31 | 2025 | Eliquis |
| Orthofix Medical, INC. | $18.49 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $14.24 | 2021 | |
| Genentech USA, INC. | $9.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Athena Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.